

Sofosbuvir/Ledipasvir (Harvoni) - HIV Antiretroviral Drug Interaction Chart

Drug Class	Agents	Interaction	Comments
NRTIs	Tenofovir	↑ tenofovir	Increase in tenofovir levels expected when used with ledipasvir. This is not an absolute contraindication and tenofovir levels are expected to increase most with ritonavir boosted PI and NNRTI and least with INSTI
	Abacavir Emtricitabine Lamivudine Zidovudine	Not studied	No interaction expected
NNRTIs	Efavirenz (when used with emtricitabine and tenofovir)	↑ tenofovir	No renal safety issues reported or loss of HIV virologic control observed. Increase in tenofovir levels expected when used with ledipasvir and efavirenz. Monitor for tenofovir-associated adverse reactions in patients receiving the combination of efavirenz, emtricitabine and tenofovir. See comments above for tenofovir.
	Nevirapine, Etravirine	Not studied	Based upon data with efavirenz, a decrease in ledipasvir levels may be possible. Not recommended.
	Rilpivirine	None observed	Use at standard dose.
Protease Inhibitors	Atazanavir/ritonavir + emtricitabine/tenofovir Darunavir/ritonavir + emtricitabine/tenofovir Lopinavir/ritonavir + emtricitabine/tenofovir	↑ tenofovir	The safety of increased tenofovir concentrations in the setting of harvoni and a HIV protease inhibitor/ritonavir has not been established. Consider alternative HCV or antiretroviral therapy to avoid increases in tenofovir exposures. If co-administration is necessary, monitor for tenofovir-associated adverse reactions. See comments above for tenofovir.
	Tipranavir/ritonavir	↓ ledipasvir ↓ sofosbuvir	Co-administration with tipranavir/ritonavir is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of sofosbuvir/ledipasvir. Co-administration is not recommended.
Integrase Inhibitors	Elvitegravir (when used with cobicistat, emtricitabine, tenofovir (Stribild))	↑ tenofovir	The safety of increased tenofovir concentrations with the combination of elvitegravir, cobicistat, emtricitabine and tenofovir has not been established. Co-administration is not recommended.
	Dolutegravir	Not studied	No interaction expected.
	Raltegravir	None observed	Use at standard dose.
Entry Inhibitors	Maraviroc	Not studied	No interaction expected.